Mallinckrodt wins orphan drug status for long-acting muscular dystrophy therapy

Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that the FDA granted orphan drug status to its long-acting cosyntropin acetate formulation, MNK-1411, for the treatment of Duchenne muscular dystrophy.
In August last year, the FDA approved the company’s request to fast track its investigational new drug application for the therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post Mallinckrodt wins orphan drug status for long-acting muscular dystrophy therapy appeared first on MassDevice.

Source: Mass Device - July 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Pharmaceuticals Wall Street Beat Mallinckrodt Source Type: news